The efficacy of larotrectinib, a tropomyosin receptor kinase (TRK) inhibitor, in TRK-fusion positive patients, including a breast cancer patient in a phase I/II trial, demonstrated promising outcomes [179]. This evidence concerns the gene NTRK1 and breast carcinoma.